STELLAMUNE MYCOPLASMA

País: Irlanda

Idioma: anglès

Font: HPRA (Health Products Regulatory Authority)

ingredients actius:

Mycoplasma hyopneumoniae strain p-5722-3

Disponible des:

Elanco Animal Health, Eli Lilly and Company Limited

Codi ATC:

QI09AB13

Designació comuna internacional (DCI):

Mycoplasma hyopneumoniae strain p-5722-3

Dosis:

Not Currently Available

formulario farmacéutico:

Emulsion for injection

tipo de receta:

POM: Prescription Only Medicine as defined in relevant national legislation

Grupo terapéutico:

Pigs

Área terapéutica:

mycoplasma

indicaciones terapéuticas:

Immunological

Estat d'Autorització:

Authorised

Data d'autorització:

2011-01-07

Fitxa tècnica

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
STELLAMUNE MYCOPLASMA
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 2 ml dose contains
ACTIVE SUBSTANCE
Inactivated_ Mycoplasma hyopneumoniae_
at least 10,529 RU* at release to ensure 6000 RU* throughout
shelf-life.
* = Relative ELISA Units
ADJUVANTS
Liquid paraffin
0.09 ml
EXCIPIENTS
Thiomersal
0.185 mg
For a full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Emulsion for injection
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Fattening pigs from one week of age.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For active immunisation of fattening pigs to reduce lung lesion scores
caused by_ Mycoplasma hyopneumoniae_
infection. Protection against_ Mycoplasma hyopneumoniae_ reduces the
impact of secondary bacterial infection with
_Pasteurella multocida_, offering improved health and economic
benefits. Immunity is acquired two weeks following the
second vaccination and protection lasts throughout the fattening
period.
4.3 CONTRAINDICATIONS
The use of immunosuppressant drugs or procedures is contraindicated
within one month of vaccination.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_1_
_1_
_/_
_0_
_5_
_/_
_2_
_0_
_1_
_5_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_0_
_7_
_8_
_0_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Vaccinate only healthy animals.
In any animal population, a small number of individuals may fail to
respond fully to vaccinat